Payment overview · 2025
General Payments
$550.86
27 reported records · 12 companies
Healthcare provider profile · identity verified
Connie Dupre, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FAYETTEVILLE, GA · NPI 1023121381
Verified facts
What the public records show
CMS Open Payments records show Connie Dupre, MD received $550.86 in general payments during 2025 across 27 reported records.
Novo Nordisk Inc accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $111.83 | 20.3% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $67.03 | 12.2% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $57.48 | 10.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $47.62 | 8.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.28 | 8.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.42 | 8.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.29 | 8.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.31 | 6.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $30.35 | 5.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.45 | 4.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.77 | 3.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.03 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $550.86 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $92.49 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $92.49 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $67.03 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $67.03 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $57.48 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $53.92 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $47.62 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $44.42 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $44.29 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.29 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $37.31 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $37.31 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $30.35 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 81 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 200 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 161 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
73 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
200 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
200 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
161 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 21 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 725 | 223 |
| Levothyroxine Sodium | Levothyroxine Sodium | 460 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 454 | 138 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 342 | 133 |
| Hydralazine Hcl | Hydralazine Hcl | 305 | 84 |
| Losartan Potassium | Losartan Potassium | 297 | 94 |
| Lisinopril | Lisinopril | 262 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 255 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 244 | 86 |
| Buspirone Hcl | Buspirone Hcl | 238 | 78 |
| Sertraline Hcl | Sertraline Hcl | 221 | 62 |
| Gabapentin | Gabapentin | 219 | 76 |
| Jardiance | Empagliflozin | 200 | 43 |
| Mirtazapine | Mirtazapine | 199 | 82 |
| Metformin Hcl | Metformin Hcl | 198 | 58 |
| Trazodone Hcl | Trazodone Hcl | 187 | 64 |
| Januvia | Sitagliptin Phosphate | 183 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 53 |
| Montelukast Sodium | Montelukast Sodium | 176 | 53 |
| Azelastine Hcl | Azelastine Hcl | 172 | 95 |
| Ezetimibe | Ezetimibe | 171 | 60 |
| Omeprazole | Omeprazole | 165 | 51 |
| Ozempic | Semaglutide | 161 | 33 |
| Potassium Chloride | Potassium Chloride | 150 | 42 |
| Simvastatin | Simvastatin | 141 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 41 |
| Famotidine | Famotidine | 117 | 39 |
| Metformin Hcl Er | Metformin Hcl | 106 | 31 |
| Allopurinol | Allopurinol | 105 | 33 |
| Carvedilol | Carvedilol | 102 | 38 |
| Furosemide | Furosemide | 97 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 32 |
| Eliquis | Apixaban | 81 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 81 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 34 |
| Synthroid | Levothyroxine Sodium | 73 | 21 |
| Tramadol Hcl | Tramadol Hcl | 73 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 22 |
| Glimepiride | Glimepiride | 65 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 64 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 23 |
| Tradjenta | Linagliptin | 60 | 11 |
| Atenolol | Atenolol | 59 | 20 |
| Farxiga | Dapagliflozin Propanediol | 55 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 16 |
| Alendronate Sodium | Alendronate Sodium | 51 | 13 |
| Clonidine Hcl | Clonidine Hcl | 50 | 13 |
| Nystatin | Nystatin | 48 | 28 |
| Bupropion Xl | Bupropion Hcl | 46 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Ketoconazole | Ketoconazole | 43 | 25 |
| Verapamil Er | Verapamil Hcl | 43 | suppressed |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Spironolactone | Spironolactone | 42 | 15 |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Nifedipine Er | Nifedipine | 38 | 13 |
| Methylprednisolone | Methylprednisolone | 35 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 12 |
| Valacyclovir | Valacyclovir Hcl | 34 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 27 |
| Meloxicam | Meloxicam | 30 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Ciclopirox | Ciclopirox | 29 | 13 |
| Glipizide | Glipizide | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Topiramate | Topiramate | 25 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 19 |
| Gemtesa | Vibegron | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 12 |
| Telmisartan | Telmisartan | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | 12 |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 14 |
| Primidone | Primidone | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Levocarnitine | Levocarnitine | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $550.86 · 27 records | Novo Nordisk Inc | AREXVY, ELIQUIS, GEMTESA, INSPIRE, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, VRAYLAR, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error